The PD-L1 biomarker testing market sales is expanding rapidly and is becoming increasingly important in the context of cancer diagnosis and treatment. PD-L1 biomarker testing is an essential component of immuno-oncology that guides the selection of immune checkpoint inhibitors as a treatment approach by determining the expression levels of PD-L1 in tumour cells. By the …
Tag Archives: PD-L1 Biomarker Testing Market Sales
PD-L1 Biomarker Testing Market to Reach US$ 1.58 Billion by 2033 with a Remarkable 9.14% CAGR
The PD-L1 biomarker testing market is projected to be valued US$ 597.9 million by the end of 2022. From 2023 to 2033, the market is projected to grow at a compound annual growth rate (CAGR) of 9.14%, with a market value of approximately US$ 1.58 billion in 2033. The demand for PD-L1 Biomarker Testing Market is …